Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Crunching Numbers to Combat Cancer

By Drug Discovery Trends Editor | September 15, 2015

UC San Francisco has received a National Cancer Institute grant of $5 million over the next five years to lead a massive effort to integrate the data from all experimental models across all types of cancer. The web-based repository is an important step in moving the fight against cancer toward precision medicine.
 
The goal is to accelerate cancer research to improve the way we diagnose, treat and conduct further research on the disease. The resulting database, called the Oncology Models Forum (OMF), will be accessible to researchers through the National Institutes of Health, to encourage scientists to use existing validated cancer models, rather than creating new ones.
 
“There are incredible new discoveries happening in cancer research today, such as detecting cancer cells and DNA in the blood stream, and even harnessing the immune system to fight cancers,” said Atul Butte, MD, PhD, director of the Institute for Computational Health Sciences at UCSF and principal investigator for the grant. “These research methodologies generate enormous amounts of data that can and should be harnessed by researchers and engineers to yield new drugs and diagnostics.”
 
Cell lines and mice have been placeholders for studying human cancer for decades, resulting in thousands of mouse models for all cancer types. While results from those studies are chronicled in scientific papers and journals, it is difficult to know how relevant the data from these experimental systems are to the actual research and development of drugs and diagnostics in actual human cancers. 
 
This is particularly important, Butte said, because there can be a gap of up to 10 years between the early basic science discoveries from experimental systems and the actual clinical trial of the drug candidates that are developed from that science, with many drug candidates failing in those clinical trials. As a result, it is critically important to ensure that early scientific discoveries are in fact relevant to human cancers, to provide every possible hope that the eventual drugs developed from those discoveries will work in clinical trials and be available to cancer patients.
 
The project aims to create an online cache of molecular data that oncologists and cancer researchers could use to validate the current models that best translate to humans, make predictions about the disease and move toward a collaborative, precision medicine approach to cancer. Ultimately, Butte said, the effort also has the potential to create computer-based cancer models that greatly reduce the need for using animals in research.
 
The project, led by the UCSF Institute for Computational Health Sciences, will collaborate with Alejandro Sweet-Cordero, MD, Julien Sage, PhD, and Nigam Shah, PhD, at Stanford University, who will provide support with the latest genetically-engineered cancer models, as well as standardized nomenclatures. It also will include bioinformatics specialists from the Northrop Grumman Corp., who will help build and maintain the online database.
 
Source: University of California, San Francisco

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE